earnings
confidence high
sentiment positive
materiality 0.75
Rapid Micro prelim Q4 rev record $8.2M, +30% YoY; Lonza collaboration
RAPID MICRO BIOSYSTEMS, INC.
2024-FY EPS reported
-$1.08
revenue$28,051,000
- Q4 total revenue preliminary ~$8.2M (record), +30% YoY; recurring rev ~$4.2M, +27% YoY.
- FY 2024 total rev ~$28.1M, +25% YoY; recurring rev ~$15.5M, +14% YoY.
- Placed 6 new Growth Direct systems in Q4; 21 systems placed in FY 2024; cumulative >160 placed globally.
- Collaborated with Lonza to integrate Growth Direct with MODA-EM; Lonza deploying across global cell and gene therapy network.
- Preliminary results unaudited; final results and 2025 outlook expected later in Q1 2025.